The present invention relates to the recombinant production of inhibin. At least one proprotein convertase cleavage site of the precursor subunits of inhibin is modified through substitution with the more efficiently processed cleavage site ISSRKKRSVSS. Further modifications include mutation of the type I receptor (ALK4) binding epitope of the beta subunit to supress activin bioactivity, and mutation of the homodimerization interface site of the beta subunit to reduce or prevent activin formation. Also disclosed are pharmaceuticals and uses of the inhibin precursor and mature inhibin.
